The global NGS informatics market is projected to reach $4.3 billion by 2030, at a CAGR of 15.4% from 2023 to 2030.
Succeeding extensive secondary and primary research and in-depth analysis of the market scenario, the report comprises the analysis of key industry drivers, restraints, challenges, and opportunities. The growth of the NGS informatics market is driven by increasing R&D investments by pharmaceutical and biotechnology companies, the rising prevalence of cancer and genetic disorders, the growing utilization of NGS in disease diagnostics and precision medicine, technological advancements in NGS informatics solutions, and government initiatives supporting large-scale genomic sequencing projects. However, data confidentiality concerns restrain the growth of this market.
The increasing adoption of NGS informatics tools among hospitals and clinical laboratories and the growing use of bioinformatics and genomic data management solutions for large-scale data analysis and interpretation are expected to create growth opportunities for the players operating in the NGS informatics market. However, the lack of skilled professionals required to operate NGS Informatics tools is a major challenge for market growth.
Based on offering, in 2023, the software segment is expected to account for the largest share of the market. NGS informatics software enables researchers to efficiently analyze, store, and securely share vast amounts of genomic data. With their cost and time-saving capabilities, robust data security measures, and seamless collaboration features, these software solutions enable effective genomic data management, contributing to the large market share of this segment.
Based on application, in 2023, the drug discovery segment is expected to account for the largest share of the market. The growth of this segment is driven by the benefits offered by NGS technology in drug discovery. NGS enables the identification of novel drug targets and the development of therapeutic techniques that target specific genes and proteins, including targeted therapies, gene therapy, and oligonucleotide therapy.
Based on end user, in 2023, the pharmaceutical & biotechnology companies segment is expected to account for the largest share of the next generation sequencing (NGS) informatics market. Pharmaceutical & biotechnology companies extensively utilize NGS for high-throughput analysis and genetic-based drug development. The adoption of NGS informatics has enabled efficient management, analysis, and reporting of large volumes of genomic data, thereby supporting remote work and enhancing research capabilities. These factors contribute to the significant market share of this segment.
An in-depth analysis of the geographical scenario of the global NGS informatics market provides detailed qualitative and quantitative insights about the five major geographies (North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa) along with the coverage of major countries in each region. In 2023, North America is expected to account for the largest share of the NGS informatics market, followed by Europe, Asia-Pacific, Latin America, and the Middle East & Africa. The factors supporting the largest share of this market are technological advancements in the region, the increasing prevalence of cancer, and increased healthcare care spending. Additionally, the presence of key players, well-established healthcare infrastructure, and government initiatives for NGS-based diagnostic testing also contribute to the large market share of North America.
The key players operating in the global NGS market are Illumina, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Qiagen N.V. (Netherlands), Agilent Technologies, Inc. (U.S.), Sapio Sciences, LLC (U.S.), DNASTAR, Inc. (U.S.), Fabric Genomics, Inc. (U.S.), Partek Incorporated (U.S.), and DNAnexus, Inc. (U.S.).
Succeeding extensive secondary and primary research and in-depth analysis of the market scenario, the report comprises the analysis of key industry drivers, restraints, challenges, and opportunities. The growth of the NGS informatics market is driven by increasing R&D investments by pharmaceutical and biotechnology companies, the rising prevalence of cancer and genetic disorders, the growing utilization of NGS in disease diagnostics and precision medicine, technological advancements in NGS informatics solutions, and government initiatives supporting large-scale genomic sequencing projects. However, data confidentiality concerns restrain the growth of this market.
The increasing adoption of NGS informatics tools among hospitals and clinical laboratories and the growing use of bioinformatics and genomic data management solutions for large-scale data analysis and interpretation are expected to create growth opportunities for the players operating in the NGS informatics market. However, the lack of skilled professionals required to operate NGS Informatics tools is a major challenge for market growth.
Based on offering, in 2023, the software segment is expected to account for the largest share of the market. NGS informatics software enables researchers to efficiently analyze, store, and securely share vast amounts of genomic data. With their cost and time-saving capabilities, robust data security measures, and seamless collaboration features, these software solutions enable effective genomic data management, contributing to the large market share of this segment.
Based on application, in 2023, the drug discovery segment is expected to account for the largest share of the market. The growth of this segment is driven by the benefits offered by NGS technology in drug discovery. NGS enables the identification of novel drug targets and the development of therapeutic techniques that target specific genes and proteins, including targeted therapies, gene therapy, and oligonucleotide therapy.
Based on end user, in 2023, the pharmaceutical & biotechnology companies segment is expected to account for the largest share of the next generation sequencing (NGS) informatics market. Pharmaceutical & biotechnology companies extensively utilize NGS for high-throughput analysis and genetic-based drug development. The adoption of NGS informatics has enabled efficient management, analysis, and reporting of large volumes of genomic data, thereby supporting remote work and enhancing research capabilities. These factors contribute to the significant market share of this segment.
An in-depth analysis of the geographical scenario of the global NGS informatics market provides detailed qualitative and quantitative insights about the five major geographies (North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa) along with the coverage of major countries in each region. In 2023, North America is expected to account for the largest share of the NGS informatics market, followed by Europe, Asia-Pacific, Latin America, and the Middle East & Africa. The factors supporting the largest share of this market are technological advancements in the region, the increasing prevalence of cancer, and increased healthcare care spending. Additionally, the presence of key players, well-established healthcare infrastructure, and government initiatives for NGS-based diagnostic testing also contribute to the large market share of North America.
The key players operating in the global NGS market are Illumina, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Qiagen N.V. (Netherlands), Agilent Technologies, Inc. (U.S.), Sapio Sciences, LLC (U.S.), DNASTAR, Inc. (U.S.), Fabric Genomics, Inc. (U.S.), Partek Incorporated (U.S.), and DNAnexus, Inc. (U.S.).
Scope of the Report:
Next Generation Sequencing (NGS) Informatics Market Assessment - by Offering
- Software
- By Type,
- Data Analysis Software
- Data Interpretation and Reporting Tools
- Data Storage and Computing Tools
- Laboratory Information Management Systems (LIMS)
- By Deployment mode,
- Web and Cloud-based
- On-premise
- NGS Informatics Services
Next Generation Sequencing (NGS) Informatics Market Assessment - by Application
- Disease Diagnoses
- Biomarker Discovery
- Drug Discovery
- Precision Medicine
- Agriculture and Animal Research
Next Generation Sequencing (NGS) Informatics Market Assessment - by End User
- Pharmaceutical and Biotechnology Companies
- Hospitals & Diagnostic Laboratories
- Academic & Research Institutes
- Other End Users
Next Generation Sequencing (NGS) Informatics Market Assessment - by Geography
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- Italy
- U.K.
- Spain
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- Rest of Asia-Pacific
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
Table of Contents
1. Introduction
2. Research Methodology
4. Market Insights
5. Next Generation Sequencing (NGS) Informatics Market Assessment-by Offering
6. Next-Generation Sequencing (NGS) Informatics Market Assessment-by Application
7. Next-Generation Sequencing (NGS) Informatics Market Assessment-by End User
8. Next-Generation Sequencing Informatics (NGS) Market Assessment - by Geography
9. Competition Analysis
10. Company Profiles (Business Overview, Financial Overview, Product Portfolio, SWOT Analysis of Top 5 Companies, and Strategic Developments)
11. Appendix
List of Tables
List of Figures
Companies Mentioned
- Illumina Inc.
- Thermo Fisher Scientific Inc.
- F. Hoffmann-La Roche Ltd.
- Qiagen N.V.
- Agilent Technologies Inc.
- Sapio Sciences LLC
- DNASTAR Inc.
- Fabric Genomics Inc.
- Partek Incorporated
- DNAnexus Inc. .
